Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 4/2012

01-04-2012 | Original Article

PDCD4 expression inversely correlated with miR-21 levels in gastric cancers

Authors: Zhang Cao, Jung Hwan Yoon, Suk Woo Nam, Jung Young Lee, Won Sang Park

Published in: Journal of Cancer Research and Clinical Oncology | Issue 4/2012

Login to get access

Abstract

Purpose

The specific aim of this study was to investigate whether the PDCD4 gene is involved in the development and progression of gastric cancer.

Methods

We examined the genetic and epigenetic alterations of the PDCD4 gene as well as the expression of PDCD4 protein in gastric cancers. The mRNA expression of PDCD4 and miRNA-21 expression were also analyzed using quantitative real-time RT-PCR.

Results

Loss or reduced PDCD4 expression was observed in 79 (36.7%) of 215 gastric cancer specimens. Statistically, altered PDCD4 expression was not associated with the clinicopathological parameters, including tumor differentiation, location, lymph node metastasis and overall survival (P > 0.05). miRNA-21 overexpression was frequently detected in gastric cancers (31 of 46, 67.4%), and there was a significant inverse correlation between miRNA-21 and PDCD4 protein expression (P = 0.029), but not between miRNA-21 and PDCD4 mRNA expression. In genetic analysis, no mutation was detected in the coding region of the PDCD4 gene, and promoter hypermethylation was found in 24 (36.4%) of the 66 gastric cancer samples.

Conclusions

Our data suggest that overexpression of miRNA-21 and reduced or loss of PDCD4 expression may play a role in the development and progression of gastric cancers.
Literature
Allgayer H (2010) Pdcd4, a colon cancer prognostic that is regulated by a microRNA. Crit Rev Oncol Hematol 73:185–191PubMedCrossRef
Asangani IA, Rasheed SA, Nikolova DA et al (2008) MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27:2128–2136PubMedCrossRef
Calin GA, Dumitru CD, Shimizu M et al (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99:15524–15529PubMedCrossRef
Chen Y, Knösel T, Kristiansen G et al (2003) Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. J Pathol 200:640–646PubMedCrossRef
Chen C, Ridzon DA, Broomer AJ et al (2005) Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33:e179PubMedCrossRef
Esquela-Kerscher A, Slack FJ (2006) Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6:259–269PubMedCrossRef
Frankel LB, Christoffersen NR, Jacobsen A et al (2008) Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 283:1026–1033PubMedCrossRef
Gao F, Wang X, Zhu F et al (2009) PDCD4 gene silencing in gliomas is associated with 5′CpG island methylation and unfavorable prognosis. J Cell Mol Med 13:4257–4267PubMedCrossRef
Goke R, Barth P, Schmidt A et al (2004) Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21(Waf1/Cip1). Am J Physiol Cell Physiol 287:C1541–C1546PubMedCrossRef
Grunau C, Clark SJ, Rosenthal A (2001) Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res 29:E65–E75PubMedCrossRef
Hiyoshi Y, Kamohara H, Karashima R et al (2009) MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res 15:1915–1922PubMedCrossRef
Johnson SM, Grosshans H, Shingara J et al (2005) RAS is regulated by the let-7 microRNA family. Cell 120:635–647PubMedCrossRef
Kononen J, Bubendorf L, Kallioniemi A et al (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844–847PubMedCrossRef
Kusenda B, Mraz M, Mayer J et al (2006) MicroRNA biogenesis, functionality, and cancer relevance. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 150:205–215PubMed
Lee JY, Dong SM, Kim SY et al (1998) A simple, precise and economical microdissection technique for analysis of genomic DNA from archival tissue sections. Virchows Arch 433:305–309PubMedCrossRef
Lehmann U, Hasemeier B, Lilischkis R et al (2001) Quantitative analysis of promoter hypermethylation in laser-microdissected archival specimens. Lab Invest 81:635–638PubMedCrossRef
Ma L, Teruya-Feldstein J, Weinberg RA (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449:682–688PubMedCrossRef
Meng F, Henson R, Wehbe-Janek H et al (2007) MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133:647–658PubMedCrossRef
Motoyama K, Inoue H, Mimori K et al (2010) Clinicopathological and prognostic significance of PDCD4 and microRNA-21 in human gastric cancer. Int J Oncol 36:1089–1095PubMed
Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45PubMedCrossRef
Scott GK, Mattie MD, Berger CE et al (2006) Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 66:1277–1281PubMedCrossRef
Shenouda SK, Alahari SK (2009) MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev 28:369–378PubMedCrossRef
Shibahara K, Asano M, Ishida Y et al (1995) Isolation of a novel mouse gene MA-3 that is induced upon programmed cell death. Gene 215:297–301CrossRef
Shin HR, Jung KM, Won YJ et al (2004) 2002 Annual report of the Korea central cancer registry: based on registered data from 139 hospitals. Cancer Res Treat 36:103–114PubMedCrossRef
Soejima H, Miyoshi O, Yoshinaga H et al (1999) Assignment of the programmed cell death 4 gene (PDCD4) to human chromosome band 10q24 by in situ hybridization. Cytogenet Cell Genet 87:113–114PubMedCrossRef
Takamizawa J, Konishi H, Yanagisawa K et al (2004) Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64:3753–3756PubMedCrossRef
Tili E, Michaille JJ, Alder H et al (2010) Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effectors of TGFβ signaling pathway in SW480 cells. Biochem Pharmacol 12:2057–2065CrossRef
Wang Q, Sun ZX, Allgayer H et al (2010) Downregulation of E-cadherin is an essential event in activating beta-catenin/Tcf-dependent transcription and expression of its target genes in Pdcd4 knockdown cells. Oncogene 29:128–138PubMedCrossRef
Wei NA, Liu SS, Leung TH et al (2009) Loss of Programmed cell death 4 (Pdcd4) associates with the progression of ovarian cancer. Mol Cancer 8:70PubMedCrossRef
Wen YH, Shi X, Chiriboga L et al (2007) Alterations in the expression of PDCD4 in ductal carcinoma of the breast. Oncol Rep 18:1387–1393PubMed
Werner M, Becker KF, Keller G et al (2001) Gastric adenocarcinoma: pathomorphology and molecular pathology. J Cancer Res Clin Oncol 127:207–216PubMedCrossRef
Yang HS, Jansen AP, Nair R et al (2001) A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-kappaB or ODC transactivation. Oncogene 20:669–676PubMedCrossRef
Yoon JH, Song JW, Zhang C et al (2011) Inactivation of the Gastrokine 1 gene in gastric adenomas and carcinomas. J Pathol 223:618–625PubMedCrossRef
Zhang Z, Li Z, Gao C et al (2008) miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest 88:1358–1366PubMedCrossRef
Zhu S, Si ML, Wu H et al (2007) MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 282:14328–14336PubMedCrossRef
Zhu S, Wu H, Wu F et al (2008) Micro-RNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 18:350–359PubMedCrossRef
Metadata
Title
PDCD4 expression inversely correlated with miR-21 levels in gastric cancers
Authors
Zhang Cao
Jung Hwan Yoon
Suk Woo Nam
Jung Young Lee
Won Sang Park
Publication date
01-04-2012
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 4/2012
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-011-1140-8

Other articles of this Issue 4/2012

Journal of Cancer Research and Clinical Oncology 4/2012 Go to the issue

Original Article

The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma

Original Article

Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth

Original Article

Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer

Original Paper

The functional MDM2 T309G genetic variant but not P53 Arg72Pro polymorphism is associated with risk of sarcomas: a meta-analysis

Original Paper

Expression of tumor suppressor gene ING4 in ovarian carcinoma is correlated with microvessel density

Original Paper

Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits